Skip to content
★ Sign in to follow
MP

M. Pykett

Board Director
Director
Pharming Group N.V.
Insider activity · 24 months2 buys0 sales
Total declarations
17
Company
1
▲ Purchases (17 ops.)
€78k
▼ Sales (0 ops.)
—

Latest filing: trade of 28 May 2026 for Pharming Group N.V.. The register gives no publication date.

Filing timeline

BuySale
M. Pykett

Insider track record

Disclosed buys
17
Disclosed sells
0
Signal history

Closed purchases

Market purchases
17
Positive at T+90
75%
Median T+90
+29.3%

Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 27 Oct 2022 · 1473 days ago · €9,174
    +12.0%
    Entry €0.99 · Close at T+365 €1.10
  • Filed 04 Aug 2022 · 1557 days ago · €7,500
    +25.5%
    Entry €0.90 · Close at T+365 €1.13
  • Filed 25 May 2022 · 1628 days ago · €7,147
    +52.3%
    Entry €0.77 · Close at T+365 €1.18
  • Filed 24 Mar 2021 · 2055 days ago · €24k
    -29.3%
    Entry €1.05 · Close at T+365 €0.74

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

M. Pykett: trading record in brief

M. Pykett is a declared insider of Pharming Group N.V. (board member), with filings sourced from AFM. The record holds 17 filings, for trades running from 24 March 2021 to 28 May 2026.

No open-market sale appears; the market trades are 17 purchases worth €78k. The amount is not disclosed for 10 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 1 purchase and no sales.

Half of the purchases are above €7,500 and half below. Of 7 purchases, 7 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 4 purchases show a median change of +29.3%, with the price up in 75% of them. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 6 June 2026: an open-market purchase, in Pharming Group N.V. This summary is built from AFM disclosures alone and does not predict where the share price will go.

Companies and markets linked to M. Pykett

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations14 total
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    38,583 shares0Gewoon aandeelAFM:194922
    Canonical exit: 26 Aug 2026 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    31,400 shares0Gewoon aandeelAFM:176245
    Canonical exit: 8 Sept 2025 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    8,487 shares0Gewoon aandeelAFM:165348
    Canonical exit: 29 Jan 2025 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    8,487 shares0Gewoon aandeelAFM:161781
    Canonical exit: 30 Oct 2024 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    9,553 shares0Gewoon aandeelAFM:159038
    Canonical exit: 27 Aug 2024 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    7,419 shares0Gewoon aandeelAFM:155755
    Canonical exit: 13 Jun 2024 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    7,234 shares0Gewoon aandeelAFM:149885
    Canonical exit: 29 Jan 2024 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    7,234 shares0Gewoon aandeelAFM:146141
    Canonical exit: 1 Nov 2023 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    7,446 shares0Gewoon aandeelAFM:143211
    Canonical exit: 22 Aug 2023 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    0AFM
    7,022 shares0Gewoon aandeelAFM:138775
    Canonical exit: 19 Jun 2023 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    €9,17430AFM
    9,760 shares@ €0.9411.8% of flowGewoon aandeelAFM:132723
    Canonical exit: 25 Jan 2023 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    €7,50030AFM
    9,760 shares@ €0.76859.6% of flowGewoon aandeelAFM:128013
    Canonical exit: 2 Nov 2022 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    €7,14730AFM
    9,300 shares@ €0.76859.2% of flowGewoon aandeelAFM:125088
    Canonical exit: 23 Aug 2022 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.

    Same trade as the filing by L. Kruimer, counted once

    €7,49930AFM
    10,220 shares@ €0.73389.6% of flowGewoon aandeelAFM:122172
    Canonical exit: 22 Jun 2022 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.

    Same trade as the filing by L. Kruimer, counted once

    €7,50030AFM
    7,241 shares@ €1.03589.6% of flowGewoon aandeelAFM:116792
    Canonical exit: 26 Jan 2022 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.

    Same trade as the filing by B. Yanni, counted once

    €15k31AFM
    14,909 shares@ €1.035819.8% of flowGewoon aandeelAFM:114817
    Canonical exit: 3 Nov 2021 (T+90)
  • ▲
    Director or Supervisory BoardExecutivesAFM delayPharming Group N.V.
    €24k26AFM
    21,997 shares@ €1.07130.3% of flowGewoon aandeelAFM:108690
    Canonical exit: 22 Jun 2021 (T+90)

17 of 14 declarations